Drugs / CLS2702C
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04689594 | Feb 2021 → Dec 2023 | esophageal cancer | CellSeed Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CLS2702C | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04689594 ↗ |
| Modality | Cell therapy | “CLS2702C (cell sheet)” NCT04689594 ↗ |
| Route | Other | “CLS2702C (cell sheet) will be transplanted to the wound site” NCT04689594 ↗ |